Compare LZM & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZM | EDIT |
|---|---|---|
| Founded | 2021 | 2013 |
| Country | Isle of Man | United States |
| Employees | 93 | N/A |
| Industry | Metal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.3M | 432.8M |
| IPO Year | N/A | 2016 |
| Metric | LZM | EDIT |
|---|---|---|
| Price | $3.75 | $3.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $7.00 | $5.30 |
| AVG Volume (30 Days) | 741.0K | ★ 2.6M |
| Earning Date | 03-19-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | $86.37 | N/A |
| Revenue Next Year | $202.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $3.07 | $1.66 |
| 52 Week High | $6.40 | $4.54 |
| Indicator | LZM | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 43.08 | 69.20 |
| Support Level | $3.62 | $3.32 |
| Resistance Level | $4.32 | $3.65 |
| Average True Range (ATR) | 0.32 | 0.23 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 22.32 | 97.30 |
Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania, and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate. Geographically, the company operates in South Africa, Australia, and the rest of the world. The majority of its revenue is generated from Australia.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.